Deepika Dhawan

Deepika Dhawan

Auto-generated profile, based on publicly available information

Deepika Dhawan

Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2017 in International Journal of Genomics
Verified
Journal Article
Open access
PDF file
CFChristopher M. Fulkerson
Christopher M. Fulkerson
DDDeepika Dhawan
Deepika Dhawan
TRTimothy L. Ratliff
Timothy L. Ratliff
NHNoah M. Hahn
Noah M. Hahn
DKDeborah W. Knapp
Deborah W. Knapp
Genomic analyses are defining numerous new targets for cancer therapy. Therapies aimed at specific genetic and epigenetic targets in cancer cells as well as expanded development of immunotherapies are placing increased demands on animal models. Traditional experimental models do not possess the collective features (cancer heterogeneity, molecular complexity, invasion, metastasis, and immune cell response) critical to predict success or failure of emerging therapies in humans. There is growing evidence, however, that dogs with specific forms of naturally occurring cancer can serve as highly relevant animal models to complement traditional models. Invasive urinary bladder cancer (invasive urothelial carcinoma (InvUC)) in dogs, for example, closely mimics the cancer in humans in pathology, molecular features, biological behavior including sites and frequency of distant metastasis, and response to chemotherapy. Genomic analyses are defining further intriguing similarities between InvUC in dogs and that in humans. Multiple canine clinical trials have been completed, and others are in progress with the aim of translating important findings into humans to increase the success rate of human trials, as well as helping pet dogs. Examples of successful targeted therapy studies and the challenges to be met to fully utilize naturally occurring dog models of cancer will be reviewed.

15 May 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
WOWonkyung Oh
Wonkyung Oh
AKAlyssa Min Jung Kim
Alyssa Min Jung Kim
DDDeepika Dhawan
Deepika Dhawan
PKPerry M. Kirkham
Perry M. Kirkham
RORaluca Ostafe
Raluca Ostafe
SLSeung-Oe Lim
Seung-Oe Lim
Immune checkpoint blockade therapy, one of the most promising cancer immunotherapies, has shown remarkable clinical impact in multiple cancer types. Despite the recent success of immune checkpoint blockade therapy, however, the response rates in patients with cancer are limited (∼20%–40%). To improve the success of immune checkpoint blockade therapy, relevant preclinical animal models are essential for the development and testing of multiple combination approaches and strategies. Companion dogs naturally develop several types of cancer that in many respects resemble clinical cancer in human patients. Therefore, the canine studies of immuno-oncology drugs can generate knowledge that informs and prioritizes new immuno-oncology therapy in humans. The challenge has been, however, that immunotherapeutic antibodies targeting canine immune checkpoint molecules such as canine PD-L1 (cPD-L1) have not been commercially available. Here, we developed a new cPD-L1 antibody as an immuno-oncology drug and characterized its functional and biological properties in multiple assays. We also evaluated the therapeutic efficacy of cPD-L1 antibodies in our unique caninized PD-L1 mice. Together, these in vitro and in vivo data, which include an initial safety profile in laboratory dogs, support development of this cPD-L1 antibody as an immune checkpoint inhibitor for studies in dogs with naturally occurring cancer for translational research. Our new therapeutic antibody and caninized PD-L1 mouse model will be essential translational research tools in raising the success rate of immunotherapy in both dogs and humans. Significance: Our cPD-L1 antibody and unique caninized mouse model will be critical research tools to improve the efficacy of immune checkpoint blockade therapy in both dogs and humans. Furthermore, these tools will open new perspectives for immunotherapy applications in cancer as well as other autoimmune diseases that could benefit a diverse and broader patient population.

31 January 2019 in Bladder Cancer
Verified
Journal Article
Open access
PDF file
DCDamini Chand
Damini Chand
DDDeepika Dhawan
Deepika Dhawan
ASAlexander Sankin
Alexander Sankin
XRXiaoxin Ren
Xiaoxin Ren
JLJuan Lin
Juan Lin
XZXingxing Zang
Xingxing Zang
Background: B7x (B7-H4/B7S1/VTCN1), an inhibitory immune checkpoint molecule is a potential therapeutic target owing to its immunosuppressive effect and well-known expression in cancers. Immune checkpoints in canine bladder cancer are largely undefined. Here, we report the first evaluation on expression of B7x in spontaneous canine invasive bladder cancer, a novel model system for the study of invasive human urothelial carcinoma. Objective: This work aims to study expression of immune checkpoint B7x in spontaneous canine invasive bladder cancer. Methods: RNA-seq analysis was performed to determine B7x expression in tumor versus normal bladder. Gene ontology (GO) study was used to explore the biological role of B7x. B7x protein expression was evaluated by immunohistochemistry (IHC). TCGA and GTEx were used to examine B7x expression in 599 human bladder urothelial carcinoma (BLCA). Results: RNA-seq analysis indicated 5.72 and 7.04 fold up regulation of B7x in tumors, using DESeq2 and edge R respectively ( p < 0.00008). B7x was closely associated with immune processes in GO analysis. IHC results revealed 60% of cases as B7x positive. B7x intensity was scored as negative in 40% ( n = 20/50), low in 24% ( n = 12/50), medium in 14% ( n = 7/50) and high in 22% ( n = 11/50) of cases. In human BLCA, B7x expression was significantly associated with worse overall survival ( p = 0.02). Conclusions: Our results suggest that B7x is over expressed in canine bladder cancer. Thus canine model can be vital in advancing the translational research on B7x, a new potential therapeutic target in human bladder cancer.

22 June 2026
Verified
Other
Open access
YHYanying He
Yanying He
JZJiaqi Zhao
Jiaqi Zhao
JKJung Suk Kim
Jung Suk Kim
MBMeaghan Broman
Meaghan Broman
SBSimone de Brot
Simone de Brot
YYYoon Yeo
Yoon Yeo
Tumor response in companion dogs.

22 June 2026
Verified
Other
Open access
YHYanying He
Yanying He
JZJiaqi Zhao
Jiaqi Zhao
JKJung Suk Kim
Jung Suk Kim
MBMeaghan Broman
Meaghan Broman
SBSimone de Brot
Simone de Brot
YYYoon Yeo
Yoon Yeo
Chemoimmunotherapy leverages the immune system to control tumor growth and develop durable antitumor immunity. With this goal, we previously developed a nanoparticulate immunoactive complex (IMAX), composed of polyethyleneimine–lithocholic acid conjugate, paclitaxel, and a cyclic dinucleotide, which showed robust antitumor activity in multiple mouse models following intratumoral administration. In this study, we evaluated the biodistribution of locally delivered IMAX and determined a safe and effective dose in mice to inform pilot safety and efficacy evaluations in dogs. In mice, IMAX remained localized at the injection site with minimal systemic exposure, induced rapid immune cell infiltration, evidenced by gross skin reactions and histologic changes, and achieved complete tumor regression even at one-fifth of the initial dose. Laboratory dogs tolerated IMAX well, with only transient, manageable adverse events. In a pilot study in companion dogs with naturally occurring cancer, IMAX administered at conservative doses induced histologic changes indicating immune cell infiltration and necrosis, accompanied by transcriptomic signatures of early innate immune pathway activation, resulting in measurable antitumor effects in the dogs with mammary carcinoma. These findings support the feasibility and safety of local IMAX therapy in tumor-bearing dogs and warrant further investigation with optimized dosing and combination strategies.Significance:Locally administered nanoparticulate IMAX induces complete tumor regression in mice and triggers rapid immune cell infiltration, while producing measurable antitumor responses in companion dogs with mammary carcinoma, supporting the translational potential.

22 June 2026
Verified
Other
Open access
YHYanying He
Yanying He
JZJiaqi Zhao
Jiaqi Zhao
JKJung Suk Kim
Jung Suk Kim
MBMeaghan Broman
Meaghan Broman
SBSimone de Brot
Simone de Brot
YYYoon Yeo
Yoon Yeo
Histology of companion dog tumors before and after IMAX treatment. A, Histology of dog RV soft tissue sarcoma. Left, perivascular lymphocytic infiltration (▲). Middle, lack of identifiable tumor cells and marked leukocytic (primarily neutrophils) infiltration with mitotically active giant cells (→). Right, perivascular lymphocytic infiltration (▲) and blue extracellular and intracellular granular materials (inset) located mainly at the tumor periphery. B, Histology of dog SP soft tissue sarcoma. Right, marked intratumoral lymphocytic infiltration (▲). C, Histology of dog CL mammary carcinomas. Ca, caudal mammary gland; Cr, cranial mammary gland. D, Histology of dog BM mammary carcinoma. Right, some areas of the tumor 3 weeks after the second treatment include both malignant epithelial (*) component and malignant mesenchymal component with osteoid (▲), characteristic of carcinosarcoma. Scale bars, 100 μm.